Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis
Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis
نویسندگان: مهرزاد حاج علیلوی بناب , محمد رضا جعفری نخجوانی , سیما عابدی آذر , سوسن کلاهی , مرتضی قوجازاده , علی اصغر ابراهیمی چهارم , آیدا مالک مهدوی , حمید نوشاد عباسپور , علیرضا خبازی اسکویی
کلمات کلیدی: lupus nephritis, mycophenolate mofetil, cyclophosphamide
نشریه: 16556 , 5 , 12 , 2018
| نویسنده ثبت کننده مقاله |
آیدا مالک مهدوی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
بیماری های بافت همبند |
| کد مقاله |
65722 |
| عنوان فارسی مقاله |
Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis |
| عنوان لاتین مقاله |
Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis |
| ناشر |
10 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Introduction. Lupus nephritis is a common and severe manifestation
of systemic lupus erythematosus that can lead to end-stage renal
disease and death. The aim of this study was to compare the efficacy
and safety of mycophenolate mofetil (MMF) and cyclophosphamide
as induction therapy and subsequently as maintenance therapy
for lupus nephritis.
Materials and Methods. In this retrospective case-control study,
67 patients with proliferative lupus nephritis who were treated
with MMF (n = 45) and pulse of intravenous cyclophosphamide
(n = 22) were included. Remission of the kidney disease, mortality,
and adverse events were evaluated and compared between the
two groups.
Results. The 45 patients treated with MMF had a mean age of
33.8 ± 10.6 years and 17.1% of them were males. The 22 patients
treated with pulse of intravenous cyclophosphamide had a mean age
of 38.1 ± 11.1 years and 18.2% of them were males. Complete and
partial kidney remission occurred in 40% and 42.2% of the patients
treated with MMF and in 31.8% and 59.1% of the patients treated
with cyclophosphamide, respectively. No significant differences
were observed in complete and partial remission between the two
groups. No mortality was reported in the studied patients. There
were no significant differences in the frequency of adverse events
between the two groups.
Conclusions. The efficacy of MMF in long-term treatment of lupus
nephritis was comparable to that of cyclophosphamide, and there
is no significant differences in the rate of side effects between the
two regimens. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| 3807-18650-1-PB.pdf | 1397/11/03 | 278400 | دانلود |